GlassScriptPhysician profile
Regina Altemus
NPI 1801316542
$2,938.40
in general payments reported to CMS, 2019-2025
21 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.98 · 2021: $236 · 2022: $140 · 2023: $285 · 2024: $614 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $360.42 | 2024-2025 | Infuse, Xiidra, Miebo |
| Lkc Technologies, INC. | $327.13 | 2023-2025 | |
| Glaukos Corporation | $306.78 | 2021-2025 | Idosetr |
| Coopervision INC. | $265.11 | 2021-2025 | Onefit Contact Lens |
| Tarsus Pharmaceuticals, INC. | $255.88 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $238.16 | 2024-2025 | Total30, Precision 1, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $197.27 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $180.28 | 2023-2025 | Cequa |
| Sight Sciences, INC. | $133.44 | 2025 | Omni Surgical System |
| Dompe US, INC. | $125.70 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $108.08 | 2024-2025 | Vevye |
| Abbvie INC. | $103.49 | 2024-2025 | |
| Rxsight INC | $84.51 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Amgen INC. | $63.32 | 2024 | Tepezza |
| Biotissue Holdings INC. | $56.10 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.13 | 2019 | |
| Oyster Point Pharma, INC. | $22.79 | 2024 | Tyrvaya |
| Thea Pharma INC. | $22.77 | 2024 | Iyuzeh |
| Ani Pharmaceuticals, INC. | $18.04 | 2025 | Purified Cortrophin Gel |
| Eyepoint US, INC. | $15.19 | 2019 | |
| Visioneering Technologies, INC. | $1.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Altemus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.